We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Avecho Biotechnology Limited is a biotechnology business based in Australia. Avecho Biotechnology shares (AVE) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Avecho Biotechnology has a trailing 12-month revenue of around $453,536. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.007 - $0.038 |
|---|---|
| 50-day moving average | $0.0171 |
| 200-day moving average | $0.0187 |
| Target price | $1.72 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.002 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.019
| 1 week (2021-09-09) | 18.75% |
|---|---|
| 1 month (2021-08-18) | 11.76% |
| 3 months (2021-06-18) | 5.56% |
| 6 months (2021-03-19) | -13.64% |
| 1 year (2020-09-18) | 137.50% |
|---|---|
| 2 years (2019-09-18) | 280.00% |
| 3 years (2018-09-18) | -20.83% |
| 5 years (2016-09-16) | -18.80% |
Valuing Avecho Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avecho Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avecho Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 million (£592,494).
The EBITDA is a measure of a Avecho Biotechnology's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $453,536 |
|---|---|
| Gross profit TTM | $240,912 |
| Return on assets TTM | -46.27% |
| Return on equity TTM | -70.29% |
| Profit margin | 0% |
| Book value | 0.003 |
| Market capitalisation | $34.9 million |
TTM: trailing 12 months
We're not expecting Avecho Biotechnology to pay a dividend over the next 12 months.
Avecho Biotechnology's shares were split on 22 April 1999.
Over the last 12 months, Avecho Biotechnology's shares have ranged in value from as little as $0.007 up to $0.038. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Avecho Biotechnology's is 2.0707. This would suggest that Avecho Biotechnology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Shares in the lithium producer are up five-fold over the last 12 months.
